Accessibility Menu
West Pharmaceutical Services Stock Quote

West Pharmaceutical Services (NYSE: WST)

$279.30
(-0.0%)
-0.09
Price as of October 22, 2025, 1:03 p.m. ET

KEY DATA POINTS

Current Price
$279.72
Daily Change
(-0.0%) $0.09
Day's Range
$277.38 - $283.54
Previous Close
$279.39
Open
$277.38
Beta
0.88
Volume
467,603
Average Volume
676,304
Market Cap
20.1B
Market Cap / Employee
$279.39M
52wk Range
$187.43 - $352.33
Revenue
-
Gross Margin
0.35%
Dividend Yield
0.30%
EPS
$6.68
CAPs Rating
-
Industry
Life Sciences Tools and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

West Pharmaceutical Services Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
WST-2.44%+1.22%+0.24%+43,966%
S&P+15.06%+95.03%+14.29%+5,167%

West Pharmaceutical Services Company Info

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$766.20M9.1%
Gross Profit$273.20M18.1%
Gross Margin35.66%2.7%
Market Cap$15.72B-34.5%
Market Cap / Employee$1.48M0.0%
Employees10.6K0.0%
Net Income$131.80M18.4%
EBITDA$199.60M17.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$509.70M14.2%
Accounts Receivable$610.30M21.6%
Inventory421.10.5%

Liabilities

Q2 2025YOY Change
Long Term Debt$286.00M78.9%
Short Term Debt$22.20M-85.6%

Ratios

Q2 2025YOY Change
Return On Assets13.11%-1.6%
Return On Invested Capital19.42%0.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$101.90M57.3%
Operating Free Cash Flow$177.10M7.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings44.5248.9635.1632.78-30.04%
Price to Book8.468.636.035.86-34.73%
Price to Sales7.668.305.645.36-36.49%
Price to Tangible Book Value8.879.036.316.12-34.83%
Price to Free Cash Flow TTM83.77110.4966.0955.88-31.18%
Enterprise Value to EBITDA105.04112.7896.4878.46-44.85%
Free Cash Flow Yield1.2%0.9%1.5%1.8%45.31%
Return on Equity17.8%17.7%17.4%17.7%-10.17%
Total Debt$307.90M$305.30M$307.40M$308.20M-1.85%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.